Skip to main content

Table 1 Association between DNMT1 promoter methylation and clinicopathological features in BRCA1-mutated breast cancer

From: Regulation of DNA methyltransferase 1 transcription in BRCA1-mutated breast cancer: a novel crosstalk between E2F1 motif hypermethylation and loss of histone H3 lysine 9 acetylation

 

n

M

(%)

UM

(%)

P

Age at diagnosis

     

1.000

≤ 50 y

30

14

35.90

16

34.78

 

> 50 y

55

25

64.10

30

65.22

 

Menstrual status

     

0.282

Premenopausal

38

20

51.28

18

39.13

 

Postmenopausal

47

19

48.72

28

60.87

 

Tumor size

     

0.164

≤ 5 cm

59

24

61.54

35

76.09

 

> 5 cm

26

15

38.46

11

23.91

 

Histological grade

     

0.006

I-II

63

23

58.97

40

86.96

 

III

22

16

41.03

6

13.04

 

LN status

     

0.014

Positive

35

22

56.41

13

28.26

 

Negative

50

17

43.59

33

71.74

 

ER status

     

0.282

Positive

47

19

48.72

28

60.87

 

Negative

38

20

51.28

18

39.13

 

PR status

     

0.269

Positive

50

20

51.28

30

65.22

 

Negative

35

19

48.72

16

34.78

 

c-erbB-2 status

     

0.378

Positive

36

19

48.72

17

36.96

 

Negative

49

20

51.28

29

63.04

 

p53 status

     

0.258

Positive

30

11

28.21

19

41.30

 

Negative

55

28

71.79

27

58.70

 

Ki67 status

     

0.030

Positive

62

33

84.62

29

63.04

 

Negative

23

6

15.38

17

36.96

 

E-cadherin status

     

0.030

Positive

68

27

69.23

41

89.13

 

Negative

17

12

30.77

5

10.87

 
  1. M, methylated; UM, unmethylated; LN, lymph node; ER, estrogen receptor; PR, progesterone receptor.
Back to article page

Molecular Cancer

ISSN: 1476-4598